We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu
Trial record 3 of 9 for:    Humacyte

Evaluation of the Safety and Efficacy of a Vascular Prosthesis for Hemodialysis Access in Patients With ESRD

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01744418
Recruitment Status : Active, not recruiting
First Posted : December 6, 2012
Last Update Posted : August 19, 2022
FGK Clinical Research GmbH
Information provided by (Responsible Party):
Humacyte, Inc.

Brief Summary:

The purpose of this study is to assess the safety and efficacy of a novel, tissue-engineered vascular prosthesis, the Human Acellular Vascular Graft, HAVG.

The HAVG is intended as an alternative to synthetic materials and to autologous grafts in the creation of vascular access for dialysis.

Condition or disease Intervention/treatment Phase
End-stage Renal Disease Kidney Failure, Chronic Device: HAVG graft implantation Not Applicable

Detailed Description:
The HAVG is a sterile, non-pyrogenic, acellular tubular graft composed of human collagens and other natural extra-cellular matrix proteins. Upon implantation, it is anticipated (based on pre-clinical studies) that the collagen-based matrix comprising the graft will be infiltrated with host cells and re-modeled by the host. This will result in a vascular structure more similar to the histological composition of the native vascular tissue that may improve graft longevity and be less likely to become infected.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Pilot Study for Evaluation of the Safety and Efficacy of Humacyte's Human Acellular Vascular Graft for Use as a Vascular Prosthesis for Hemodialysis Access in Patients With End-Stage Renal Disease
Actual Study Start Date : November 22, 2012
Actual Primary Completion Date : December 2014
Estimated Study Completion Date : December 2024

Arm Intervention/treatment
Experimental: HAVG graft
HAVG graft implantation to study participants.
Device: HAVG graft implantation
Patients will be implanted with a Human Acellular Vascular Graft (HAVG) in the forearm or upper arm (arterial anastomosis to the radial or brachial artery, venous anastomosis to either the brachial, cephalic or very central basilica vein) using standard vascular surgical techniques. The graft will be placed in a straight or curved configuration in the first 10 patients. Loop grafts may be permitted in subsequent patients subject to acceptable graft performance at the interim safety review. Placing the graft across the elbow will be avoided.
Other Name: Human Acellular Vascular Graft

Primary Outcome Measures :
  1. HAVG safety & tolerability [ Time Frame: At each visit within first 6 months after HAVG implantation. ]
    The incidence of aneurysm formation, anastomotic bleeding or rupture, graft infection and irritation/inflammation/infection at the implantation site will be tabulated by visit and overall.

  2. HAVG patency rate [ Time Frame: At 6 months after HAVG implantation. ]
    Determine the patency (primary, primary assisted and secondary) rate of the Humacyte HAVG.

Secondary Outcome Measures :
  1. PRA response [ Time Frame: At screening, day 15, 29, 57 and week 12, 26 ]
    Assess changes in the PRA response over the 6 months after graft implantation.

  2. IgG antibodies [ Time Frame: At screening, day 15, 29, 57 and week 12, 26 ]
    Determine whether IgG antibodies to the extracellular matrix material are formed in response to implantation of the HAVG.

  3. Patency maintenance/restoration [ Time Frame: At each visit except screening. ]
    Determine the rates of interventions needed to maintain / restore patency in the graft.

  4. HAVG patency rates [ Time Frame: At 12, 18, 24 months after HAVG implantation. ]
    Patency rates (primary, primary assisted and secondary) at 12, 18 and 24 months.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with end stage renal disease (ESRD) who are not, or who are no longer, candidates for creation of an autogenous AV fistula and therefore need placement of an AV graft in the upper extremity to start or maintain hemodialysis therapy
  • Patients between 18 and 75 years old, inclusive
  • Suitable anatomy for implantation of straight forearm grafts or curved upper arm grafts (arterial anastomosis to radial or brachial artery, venous anastomosis to either brachial cephalic or very central basilica vein)
  • Hemoglobin ≥8g/dL and platelet count ≥100,000/mm3 prior to Day 1
  • Other hematological and biochemical parameters within a range consistent with ESRD and acceptable for the administration of general anesthesia prior to Day 1
  • Adequate liver function, defined as serum bilirubin ≤1.5 mg/dL; GGT, AST, ALT, and alkaline phosphatase ≤2x upper limit of normal or INR ≤ 1.5 prior to Day 1.
  • Ability to communicate meaningfully with investigative staff, competence to give written informed consent, and ability to comply with entire study procedures
  • Able and willing to give informed consent
  • Life expectancy of at least 1 year

Exclusion Criteria:

  • History or evidence of severe cardiac disease (NYHA Functional Class III or IV), myocardial infarction within six months of study entry (Day 1), ventricular tachyarrhythmias requiring continuing treatment, or unstable angina
  • History or evidence of severe peripheral vascular disease in the upper limbs
  • Known or suspected central vein obstruction on the side of planned graft implantation
  • Stroke within six (6) months of study entry (Day 1)
  • Treatment with any investigational drug or device within 60 days prior to study entry (Day 1)
  • Treatment with vitamin K-antagonists or direct thrombin inhibitors within the previous month to study entry (Day 1)
  • All patients (including both female patients of childbearing potential and male patients with childbearing potential partners) who do not use a highly effective method of birth control (failure rate less than 1% per year when used consistently and correctly), e.g. implants, injectables, combined oral contraceptives in combination with a barrier method, some intrauterine contraceptive devices, sexual abstinence, or a vasectomized partner
  • Active diagnosis of cancer within the previous year
  • Immunodeficiency including AIDS / HIV
  • Documented hypercoagulable state or history of 2 or more DVTs or other spontaneous intravascular thrombotic events
  • Bleeding diathesis
  • Active autoimmune disease
  • Previous PTFE graft in the operative limb unless the HAVG can be placed more proximally than the previous failed graft
  • More than 1 failed PTFE graft in the operative limb
  • Active local or systemic infection (WBC > 15,000/mm3)
  • Patients receiving a forearm graft with which crosses the elbow
  • Patients receiving an upper arm graft with arterial anastomosis to the axillary artery or venous anastomosis to the axillary vein
  • Patients receiving a lower extremity AV access
  • Known serious allergy to aspirin or penicillin
  • Any other condition which in the judgment of the investigator would preclude adequate evaluation of the safety and efficacy of the HAVG
  • Previous enrollment in this study
  • Employees of the sponsor or patients who are employees or relatives of the investigator
  • PRA > 20% (first 10 patients only)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01744418

Layout table for location information
Department of Vascular Surgery and Angiology at the Medical University Lublin
Lublin, Poland, 20-081
Independent Public Central Clinical Hospital in Warsaw; Department of General, Vascular and Transplant Surgery
Warsaw, Poland, 02-097
Regional Specialist Hospital in Wroclaw; Clinic of Vascular Surgery
Wroclaw, Poland, 51-124
Sponsors and Collaborators
Humacyte, Inc.
FGK Clinical Research GmbH
Layout table for investigator information
Study Director: Shamik Parikh, MD Humacyte, Inc.
Additional Information:
Publications of Results:
Layout table for additonal information
Responsible Party: Humacyte, Inc.
ClinicalTrials.gov Identifier: NCT01744418    
Other Study ID Numbers: CLN-PRO-V001
First Posted: December 6, 2012    Key Record Dates
Last Update Posted: August 19, 2022
Last Verified: August 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Humacyte, Inc.:
Renal Dialysis
Blood Vessel Prosthesis
Tissue-Engineered Vascular Graft
Vascular Prosthesis Implantation
Additional relevant MeSH terms:
Layout table for MeSH terms
Kidney Diseases
Kidney Failure, Chronic
Renal Insufficiency
Urologic Diseases
Renal Insufficiency, Chronic